Latest Advances in Lung Cancer Research

The FDA has granted nivolumab (Opdivo) priority review as a neoadjuvant treatment for resectable NSCLC, based on promising CheckMate -816 trial results.

Five Year Lung Cancer Survival Update: Pembrolizumab continued to improve OS than docetaxel in patients with PD-L1 TPS ≥50% and TPS ≥1%.

Imfinzi increases five year survival to 43% in patients with Stage III non-small cell lung cancer. After treatment, 43% survive 5+ years.

Immuno-oncology effectiveness in medicare population is the subject of a study of 20,000 Medicare patients published in JAMA.

Immunotherapy for early-stage lung cancer is the focus of a study presented at the American Society of Clinical Oncology (ASCO) annual meeting.

Latest research shows the level of chromosomal abnormality in lung cancer patients may predict their immunotherapy response.

Research shows using both immunotherapy and chemotherapy for treatment doubles survival among those diagnosed with lung cancer.

KRAS mutation, previously seen as “undruggable” sees promise for new therapies through improbable targets for lung cancer.

Merck pulls Keytruda for SCLC. Pharmaceutical company, Merck announced plans to pull Ketruda for SCLC due to disappointing results from Phase III trial.